TY  - GEN
AU  - López,José I.
TI  - Renal Cell Carcinoma
SN  - books978-3-03928-639-3
PY  - 2020///
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - N-glycomapping
KW  - n/a
KW  - SMAD proteins
KW  - patient survival
KW  - pro-IL-1?
KW  - survival prediction
KW  - inflammation markers
KW  - tumor migration
KW  - prognostic factors
KW  - practical approach
KW  - circular RNAs in a clinico-genomic predictive model
KW  - glycomarkers
KW  - review
KW  - nephrectomy
KW  - uric acid
KW  - VEGF inhibitors
KW  - metabolic reprogramming
KW  - collecting duct carcinoma
KW  - curcumin
KW  - metabolome profiling
KW  - identification of circular RNAs
KW  - IL-2
KW  - experimental validation of circular RNA
KW  - Raf/MEK/ERK
KW  - HOT
KW  - PI3K/Akt/mTOR
KW  - pentose phosphate pathway
KW  - kidney cancer
KW  - LOT
KW  - mutation
KW  - RCC
KW  - polybromo-1
KW  - pale cell
KW  - MMP-9
KW  - gene expression
KW  - recurrence free survival
KW  - chromosomal loss
KW  - IL-1?
KW  - chronic kidney disease
KW  - glutathione transferase omega 2
KW  - label-free
KW  - glutathione transferase omega 1
KW  - emerging entity
KW  - copy number alteration
KW  - FOXO3
KW  - predictive role
KW  - tumor slice culture
KW  - tyrosine kinase inhibitors
KW  - PPP
KW  - ESC
KW  - CDKN1A expression
KW  - metastasis
KW  - PD-L1
KW  - diagnostic and prognostic markers
KW  - EVI1
KW  - copy number loss
KW  - RNA sequencing
KW  - NK cells
KW  - glutathione metabolism
KW  - clear cell renal cell carcinoma
KW  - renal cell cancer
KW  - proliferation
KW  - eosinophilic variant
KW  - Xp11 translocation renal cell carcinoma
KW  - prognosis
KW  - invasion
KW  - immune infiltration
KW  - IL4R?
KW  - FISH
KW  - 11) translocation renal cell carcinoma
KW  - tumor microenvironment
KW  - metabolome
KW  - hyperosmolality
KW  - toxicity
KW  - ALK
KW  - drug sensitivity
KW  - t(6
KW  - copy number analysis
KW  - urine
KW  - genetic association
KW  - polymorphism
KW  - solute carrier proteins
KW  - kidney
KW  - metastatic ccRCC
KW  - molecular genetic features
KW  - recurrence-free survival
KW  - chromophobe renal cell carcinoma
KW  - unclassified renal tumor
KW  - overall survival
KW  - mTOR inhibitors
KW  - mTOR
KW  - JAK2
KW  - von Hippel-Lindau
KW  - miR-155-5p
KW  - glycoproteomics
KW  - PBRM1
KW  - miR-133b
KW  - survival
KW  - TFE3
KW  - TFEB
KW  - oncocytic renal tumor
KW  - immune checkpoint inhibitors
KW  - biomarker
KW  - MMP10
KW  - TCGA
KW  - ghrelin
KW  - EMT like
KW  - checkpoint inhibitors
KW  - MiT family translocation renal cell carcinoma
KW  - gene signature
KW  - sarcomatoid
KW  - transforming growth factor beta
KW  - clear cell Renal Cell Carcinoma
KW  - tumor adhesion
KW  - renal cancer
KW  - unclassified renal cell carcinoma
KW  - Papillary renal cell carcinoma (pRCC)
KW  - miR-146a-5p
KW  - renal cell
KW  - everolimus
KW  - integrins
KW  - cytoreductive nephrectomy
KW  - immunotherapy
KW  - predictive factors
KW  - immunohistochemistry
KW  - MTA2
KW  - IL13R?1
KW  - targeted therapy
KW  - intratumour heterogeneity
KW  - aurora A
KW  - TCA cycle
KW  - AMP-activated protein kinases
KW  - cancer-specific survival
KW  - programmed death-ligand 1
KW  - efficacy
KW  - renal cell carcinoma
KW  - anaplastic lymphoma kinase rearrangement
KW  - TFEB-amplified renal cell carcinoma
KW  - statins
KW  - cancer immunotherapy
KW  - microRNA
KW  - new entity
KW  - proteome profiling
N1  - Open Access
N2  - Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70-80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe-oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews
UR  - https://mdpi.com/books/pdfview/book/2229
UR  - https://directory.doabooks.org/handle/20.500.12854/58186
ER  -